A major study by Cochrane reviewers published this week in the BMJ brings into question the system of drug regulation and evaluation. In the culmination of a four year fight to get hold of previously unpublished data from industry, Tom Jefferson and his colleagues have published their review, which shows that the evidence that led to the worldwide stockpiling of Tamiflu (oseltamivir) and Relenza (zanamivir) was incomplete and biased.
Returning from the excellent and inspiring FMLM annual conference in Edinburgh, I was reflecting on the styles of leadership that I had observed, and what I could learn from them.
I am fortunate that some of my experiences of late have been outside the normal sphere of hospital practiceand recently had the privilege of co-leading a multi-professional medical team at an international sports tournament.